Unknown PHASE1 INTERVENTIONAL 1-arm NCT02616848

Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-negative Breast Cancers

Sponsor: Istituti Ospitalieri di Cremona

Conditions Triple Negative Breast Cancer

Updated 6 times since 2017 Last updated: Nov 25, 2015 Started: Nov 30, 2015 Primary completion: Nov 30, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02616848, this PHASE1 trial focuses on Triple Negative Breast Cancer and remains ongoing. Sponsored by Istituti Ospitalieri di Cremona, it has been updated 6 times since 2015, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE1
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE1
Feb 2018 — Jun 2018 [monthly]

Unknown Status PHASE1

Status: Recruiting → Unknown Status

▶ Show 1 earlier version

Jan 2017 — Feb 2018 [monthly]

Recruiting PHASE1

First recorded

Nov 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Istituti Ospitalieri di Cremona

Data source: Istituti Ospitalieri di Cremona

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Cremona, Italy